Neurocrine Biosciences (NBIX) Free Cash Flow Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.61% |
| Dec 31, 2025 | 35.77% |
| Sep 30, 2025 | 62.61% |
| Jun 30, 2025 | -1.38% |
| Mar 31, 2025 | 9.29% |
| Dec 31, 2024 | 13.60% |
| Sep 30, 2024 | 13.08% |
| Jun 30, 2024 | 2.56% |
| Mar 31, 2024 | 25.01% |
| Dec 31, 2023 | 34.70% |
| Sep 30, 2023 | 23.57% |
| Jun 30, 2023 | 66.46% |
| Mar 31, 2023 | -26.73% |
| Dec 31, 2022 | 32.67% |
| Sep 30, 2022 | 52.05% |
| Jun 30, 2022 | 37.90% |
| Mar 31, 2022 | 11.27% |
| Dec 31, 2021 | 29.95% |
| Sep 30, 2021 | 28.89% |
| Jun 30, 2021 | 51.94% |